incretin mimetic agents glp 1 receptor agonists Glucagon-like Peptide-1 (GLP-1) AGONIST - Mimetics Efficacy and safety of incretin

Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes

Sleep apnea: types, mechanisms, and clinical cardiovascular consequences

Collectively, these findings suggest that GLP-1R activation may have a protective role in schizophrenia, anxiety disorders, autism, and bipolar disorder, though further validation through non-genetic epidemiological studies and clinical trials is warranted

Analysts predict this figure could quadruple over the next decade, reaching or even exceeding $150 billion by the early 2030s, particularly as the drugs' therapeutic applications expand

The clinical efficacy of once-weekly exenatide was examined in multiple phase 3 studies, including the DURATION program (Diabetes Therapy Utilization: Researching changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly)